PRECIOUS trial

PRECIOUS trial - PRECIOUS trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021514

Enrollment

370

Registered

2016-03-17

Start date

2016-03-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced and recurrent breast cancer

Interventions

pertuzumab 420mg/kg iv every 3 week trasuzumab 6mg/kg iv every 3 week other chemotherapy(docetaxel, paclitaxel,nab-packitaxel,vinorerbin) trasuzumab 6mg/kg iv every 3 week other chemotherapy(doceta

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1

Exclusion criteria

Exclusion criteria: 2

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Countries

Japan

Contacts

Public Contactken-ichi Ito

Shinshu unniversity, department of medicine Surgery(2)

kenito@shinshu-u.ac.jp0263-37-2657

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026